Sarcopenia is associated with a greater risk of polypharmacy and number of medications: a systematic review and meta‐analysis
暂无分享,去创建一个
O. Bruyère | M. Barbagallo | David Steven Scott | M. Petrovic | N. Veronese | A. Cherubini | Yannis Dionyssiotis | K. Kechagias | M. Cesari | K. Ibrahim | J. Reginster | P. Giannos | K. Prokopidis | Konstantinos K Triantafyllidis
[1] R. Kressig,et al. Impact of sarcopenia on daily functioning: a cross-sectional study among older inpatients , 2022, Aging Clinical and Experimental Research.
[2] W. O’Brien,et al. Sarcopenia Prevalence and Risk Factors among Residents in Aged Care , 2022, Nutrients.
[3] Hermann W. Haller,et al. Diabetes, sarcopenia and chronic kidney disease; the Screening for CKD among Older People across Europe (SCOPE) study , 2022, BMC Geriatrics.
[4] G. Trifirò,et al. Italian guidelines on management of persons with multimorbidity and polypharmacy , 2022, Aging Clinical and Experimental Research.
[5] H. Wakabayashi,et al. Deprescribing Leads to Improved Energy Intake among Hospitalized Older Sarcopenic Adults with Polypharmacy after Stroke , 2022, Nutrients.
[6] A. Okayama,et al. Prevalence of Sarcopenia and Its Association with Quality of Life, Postural Stability, and Past Incidence of Falls in Postmenopausal Women with Osteoporosis: A Cross-Sectional Study , 2022, Healthcare.
[7] H. Yavuzer,et al. Association of sarcopenia with geriatric syndromes and neutrophil / lymphocyte ratio , 2022, Medicine Science | International Medical Journal.
[8] A. Coats,et al. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021 , 2021, Journal of cachexia, sarcopenia and muscle.
[9] J. H. Kim,et al. Metformin induces muscle atrophy by transcriptional regulation of myostatin via HDAC6 and FoxO3a , 2021, Journal of cachexia, sarcopenia and muscle.
[10] P. Sourtzi,et al. Sarcopenia and polypharmacy among older adults: A scoping review of the literature. , 2021, Archives of gerontology and geriatrics.
[11] P. Salaris,et al. Prevalence of obesity and diabetes in older people with sarcopenia defined according to EWGSOP2 and FNHI criteria , 2021, Aging Clinical and Experimental Research.
[12] E. D. de Oliveira,et al. Prevalence of sarcopenia according to EWGSOP1 and EWGSOP2 in older adults and their associations with unfavorable health outcomes: a systematic review , 2021, Aging Clinical and Experimental Research.
[13] P. Lai,et al. Sarcopenia is independently associated with parietal atrophy in older adults , 2021, Experimental Gerontology.
[14] G. Gartlehner,et al. Restricting evidence syntheses of interventions to English-language publications is a viable methodological shortcut for most medical topics: a systematic review: Excluding English-language publications a valid shortcut. , 2021, Journal of clinical epidemiology.
[15] E. Mayo-Wilson,et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews , 2021, BMJ.
[16] M. Wehling,et al. Polypharmacy in older adults: a narrative review of definitions, epidemiology and consequences , 2021, European Geriatric Medicine.
[17] G. Onder,et al. Relationship between frailty and drug use among nursing homes residents: results from the SHELTER study , 2021, Aging Clinical and Experimental Research.
[18] Min Wu,et al. Research progress of gut microbiota and frailty syndrome , 2021, Open medicine.
[19] G. Ashuntantang,et al. Geriatric syndromes in an urban elderly population in Cameroon: a focus on disability, sarcopenia and cognitive impairment , 2020, The Pan African medical journal.
[20] N. Rodondi,et al. Potentially inappropriate medication and attitudes of older adults towards deprescribing , 2020, PloS one.
[21] M. Wiese,et al. Alterations in drug disposition in older adults: a focus on geriatric syndromes , 2020, Expert opinion on drug metabolism & toxicology.
[22] J. Tomás,et al. Functional and Clinical Characteristics for Predicting Sarcopenia in Institutionalised Older Adults: Identifying Tools for Clinical Screening , 2020, International journal of environmental research and public health.
[23] P. Lee,et al. The prevalence and factors associated with sarcopenia among community living elderly with type 2 diabetes mellitus in primary care clinics in Malaysia , 2020, PloS one.
[24] E. L. Rosado,et al. The prevalence and risk factors for sarcopenia in older adults and long-living older adults. , 2020, Archives of gerontology and geriatrics.
[25] Hee-Won Jung,et al. Sarcopenia is associated with severe erectile dysfunction in older adults: a population-based cohort study , 2020, The Korean journal of internal medicine.
[26] S. Robinson,et al. The identification of probable sarcopenia in early old age based on the SARC-F tool and clinical suspicion: findings from the 1946 British birth cohort , 2020, European Geriatric Medicine.
[27] B. Hanratty,et al. Adverse Outcomes of Polypharmacy in Older People: Systematic Review of Reviews. , 2020, Journal of the American Medical Directors Association.
[28] T. Rummans,et al. Polypharmacy in older adults: the role of the multidisciplinary team , 2020, Hospital practice.
[29] A. Murray,et al. An overview of prevalence, determinants and health outcomes of polypharmacy , 2020, Therapeutic advances in drug safety.
[30] Hee-Won Jung,et al. Characteristics of sarcopenia by European consensuses and a phenotype score , 2019, Journal of cachexia, sarcopenia and muscle.
[31] P. Abete,et al. Comparing EWGSOP2 and FNIH Sarcopenia Definitions: Agreement and Three-Year Survival Prognostic Value in Older Hospitalized Adults. The GLISTEN Study. , 2019, The journals of gerontology. Series A, Biological sciences and medical sciences.
[32] V. Welch,et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. , 2019, The Cochrane database of systematic reviews.
[33] G. McGwin,et al. Metformin blunts muscle hypertrophy in response to progressive resistance exercise training in older adults: A randomized, double‐blind, placebo‐controlled, multicenter trial: The MASTERS trial , 2019, Aging cell.
[34] S. Labeeb,et al. Prevalence and Risk of Polypharmacy among Community-Dwelling, Elderly Kuwaiti Patients , 2019, Medical Principles and Practice.
[35] C. Cooper,et al. Sarcopenia and health-related outcomes: an umbrella review of observational studies , 2019, European Geriatric Medicine.
[36] Kengo Hirayama,et al. Sarcopenia Prevalence and Risk Factors among Japanese Community Dwelling Older Adults Living in a Snow-Covered City According to EWGSOP2 , 2019, Journal of clinical medicine.
[37] P. Abete,et al. Polypharmacy and sarcopenia in hospitalized older patients: results of the GLISTEN study , 2019, Aging Clinical and Experimental Research.
[38] René Rizzoli,et al. Sarcopenia: revised European consensus on definition and diagnosis , 2018, Age and ageing.
[39] S. Niida,et al. Association Between Appetite and Sarcopenia in Patients With Mild Cognitive Impairment and Early-Stage Alzheimer's Disease: A Case-Control Study , 2018, Front. Nutr..
[40] F. Buttgereit,et al. Prevalence of sarcopenia in systemic sclerosis: assessing body composition and functional disability in patients with systemic sclerosis. , 2018, Nutrition.
[41] P. Kardas,et al. Polypharmacy prevalence among older adults based on the survey of health, ageing and retirement in Europe. , 2018, Archives of gerontology and geriatrics.
[42] F. Yakaryılmaz,et al. Health‐related quality of life and fall risk associated with age‐related body composition changes; sarcopenia, obesity and sarcopenic obesity , 2018, Internal medicine journal.
[43] H. Wakabayashi,et al. Prevalence of sarcopenia and association with oral health‐related quality of life and oral health status in older dental clinic outpatients , 2018, Geriatrics & gerontology international.
[44] J. Chen,et al. Prevalence of sarcopenia and associated factors in hospitalised older patients: A cross‐sectional study , 2018, Australasian journal on ageing.
[45] B. Dong,et al. A sarcopenia screening test predicts mortality in hospitalized older adults , 2018, Scientific Reports.
[46] T. Gustafsson,et al. High doses of anti‐inflammatory drugs compromise muscle strength and hypertrophic adaptations to resistance training in young adults , 2018, Acta physiologica.
[47] Hee-Won Jung,et al. Comparisons of predictive values of sarcopenia with different muscle mass indices in Korean rural older adults: a longitudinal analysis of the Aging Study of PyeongChang Rural Area , 2018, Clinical interventions in aging.
[48] Gillian E. Caughey,et al. What is polypharmacy? A systematic review of definitions , 2017, BMC Geriatrics.
[49] P. Abete,et al. The incidence of sarcopenia among hospitalized older patients: results from the Glisten study , 2017, Journal of cachexia, sarcopenia and muscle.
[50] P. Abete,et al. Physical Activity Scale for the Elderly (PASE) Score Is Related to Sarcopenia in Noninstitutionalized Older Adults , 2017, Journal of geriatric physical therapy.
[51] Reshma Aziz Merchant,et al. Screening for Frailty and Sarcopenia Among Older Persons in Medical Outpatient Clinics and its Associations With Healthcare Burden. , 2017, Journal of the American Medical Directors Association.
[52] E. Dent,et al. Sarcopenia and post-hospital outcomes in older adults: A longitudinal study. , 2017, Archives of gerontology and geriatrics.
[53] L. Hogg. The Role of the Multidisciplinary Team , 2017 .
[54] S. Brennan-Olsen,et al. Musculoskeletal decline and mortality: prospective data from the Geelong Osteoporosis Study , 2016, Journal of cachexia, sarcopenia and muscle.
[55] B. Dong,et al. Sarcopenia predicts readmission and mortality in elderly patients in acute care wards: a prospective study , 2016, Journal of cachexia, sarcopenia and muscle.
[56] E. Steinhagen-Thiessen,et al. Polypharmacy as a Risk Factor for Clinically Relevant Sarcopenia: Results From the Berlin Aging Study II , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.
[57] R. Dziewas,et al. Impact of Sarcopenia on One-Year Mortality Among Older Hospitalized Patients with Impaired Mobility , 2017, The Journal of Frailty & Aging.
[58] W. Chie,et al. Sarcopenia Screened With SARC-F Questionnaire Is Associated With Quality of Life and 4-Year Mortality. , 2016, Journal of the American Medical Directors Association.
[59] T. Zimmers,et al. Cancer and Chemotherapy Contribute to Muscle Loss by Activating Common Signaling Pathways , 2016, Front. Physiol..
[60] A. Yalçın,et al. Sarcopenia prevalence and factors associated with sarcopenia in older people living in a nursing home in Ankara Turkey , 2016, Geriatrics & gerontology international.
[61] S. Güven,et al. Ultrasonographic evaluation of the calf muscle mass and architecture in elderly patients with and without sarcopenia. , 2016, Archives of gerontology and geriatrics.
[62] F. Landi,et al. Anorexia of Aging: Risk Factors, Consequences, and Potential Treatments , 2016, Nutrients.
[63] B. Dong,et al. Prevalence of Sarcopenia and Associated Factors in Chinese Community-Dwelling Elderly: Comparison Between Rural and Urban Areas. , 2015, Journal of the American Medical Directors Association.
[64] J. Reginster,et al. Quality of life and physical components linked to sarcopenia: The SarcoPhAge study , 2015, Experimental Gerontology.
[65] G. Klein. THE EFFECT OF GLUCOCORTICOIDS ON BONE AND MUSCLE. , 2015, Osteoporosis and sarcopenia.
[66] F. Blyth,et al. Sarcopenia Is Associated With Incident Disability, Institutionalization, and Mortality in Community-Dwelling Older Men: The Concord Health and Ageing in Men Project. , 2015, Journal of the American Medical Directors Association.
[67] G. Onder,et al. Association of sarcopenia with short- and long-term mortality in older adults admitted to acute care wards: results from the CRIME study. , 2014, The journals of gerontology. Series A, Biological sciences and medical sciences.
[68] V. Figueiredo,et al. Ibuprofen treatment blunts early translational signaling responses in human skeletal muscle following resistance exercise. , 2014, Journal of applied physiology.
[69] F. Akçiçek,et al. Sarcopenia assessment project in the nursing homes in Turkey , 2014, European Journal of Clinical Nutrition.
[70] O. Andersen,et al. Potentially inappropriate medication related to weakness in older acute medical patients , 2014, International Journal of Clinical Pharmacy.
[71] R. Schwinger,et al. Cardio-selective beta-blocker: pharmacological evidence and their influence on exercise capacity. , 2013, Cardiovascular therapeutics.
[72] G. Onder,et al. Recommendations to Prescribe in Complex Older Adults: Results of the CRIteria to Assess Appropriate Medication Use Among Elderly Complex Patients (CRIME) Project , 2013, Drugs & Aging.
[73] Andrea Russo,et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. , 2012, Clinical nutrition.
[74] J. Ioannidis,et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials , 2011, BMJ : British Medical Journal.
[75] T. Trappe,et al. Influence of acetaminophen and ibuprofen on skeletal muscle adaptations to resistance exercise in older adults. , 2011, American journal of physiology. Regulatory, integrative and comparative physiology.
[76] L. Goodyear,et al. Exercise, MAPK, and NF-κB signaling in skeletal muscle , 2007 .
[77] I. Hozo,et al. Estimating the mean and variance from the median, range, and the size of a sample , 2005, BMC medical research methodology.
[78] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[79] K. Slim,et al. Methodological index for non‐randomized studies (MINORS): development and validation of a new instrument , 2003, ANZ journal of surgery.